LCZ 696 key intermediates

Sinobright Pharma initiated and invested the project of LCZ 696 key intermediates and received technical patents related to synthetic routes. Comparing to other manufacturers, we have significant advantages in production technology and cost.

Innovator has established a rigorous patent network for LCZ696. The patent for the synthesis of intermediate 50-1, starting from epichlorohydrin, expires in September 2033. Greencait has developed a process route with independent intellectual property rights. After the patent for LCZ696 compound expires in November 2026, the product can be fully launched on the market.